Latest Derivatives News

Eclipse Metals has initiated metallurgical testing on its Grønnedal Rare Earths Project in Greenland, focusing on magnetic separation techniques to unlock the deposit’s potential. Core samples from recent drilling are en route to Perth for analysis, while strategic engagement with global partners continues.

NeuroScientific Biopharmaceuticals reports encouraging clinical responses in fistulising Crohn’s disease patients treated under Australia’s Special Access Scheme, setting the stage for pivotal Phase 2 trials later this year.

GQG Partners reported a slight decline in funds under management to USD 163.9 billion at the end of 2025, despite significant net outflows, buoyed by strong investment performance throughout the year.

SKS Technologies has completed the acquisition of Delta Elcom, a Sydney-based data centre infrastructure specialist, in a $12.5 million deal combining cash and shares. This move aims to strengthen SKS’s foothold in the NSW data centre market and expand its electrical and communications services.

Robex Resources shareholders have overwhelmingly approved a merger with Predictive Discovery Limited, setting the stage for a combined entity targeting over 400,000 ounces of gold production annually by 2029.

Arovella Therapeutics has taken a significant step forward by submitting an IND application to the U.S. FDA for its lead CAR-iNKT cell therapy, ALA-101, targeting blood cancers. This milestone paves the way for a first-in-human Phase 1 trial in both Australia and the U.S.

Westpac Banking Corporation has announced a fully franked distribution of AUD 1.1789 per Westpac Capital Notes 10 for the quarter ending March 2026, reflecting a 4.78% annualised yield based on current market rates.

Elixir Energy has been granted a 15-year retention license over its entire ATP2044 permit in Queensland’s Taroom Trough, securing 1,362 BCFe of 2C Contingent Gas Resources confirmed by the Daydream-2 well.

360 Capital Group (ASX, TGP) has received an unconditional on-market takeover bid from TT Investments at $0.31 per stapled security. The Independent Board Committee unanimously recommends acceptance, supported by an Independent Expert's fair and reasonable opinion.

INOVIQ Limited has reported compelling preclinical results for its CAR-NK-exosome therapy targeting triple-negative breast cancer, showing significant tumor reduction and perfect survival in treated mice.

Credit Clear Limited has agreed to acquire DTS, a SaaS collections business with a 35-year history, for A$7.75 million, enhancing its digital platform and global footprint. The deal is expected to be earnings accretive and unlock new growth opportunities across multiple international markets.

Bio-Gene Technology reports promising progress on its US Department of Defense-funded insecticide projects, with early mosquito mortality evidence from its Flavocide wearable device and pending launch of its Qcide indoor spray program.